Literature DB >> 8297469

Pit-1/GHF-1 expression in pituitary adenomas: further analogy between human adenomas and rat SMtTW tumours.

M Delhase1, P Vergani, A Malur, B Velkeniers, E Teugels, J Trouillas, E L Hooghe-Peters.   

Abstract

Adenomas can develop from each cell type of the anterior pituitary. In the normal pituitary, three of these cells types, the GH-, prolactin- and TSH-secreting cells, express the transcription factor Pit-1/GHF-1 which is responsible for prolactin and GH (and probably TSH) cell commitment, differentiation, probably proliferation and gene expression. We have analysed the expression of Pit-1/GHF-1 in a panel of human pituitary adenomas. All GH-, prolactin- and TSH-expressing adenomas studied expressed the Pit-1/GHF-1 factor, as demonstrated by in-situ hybridization and immunocytochemistry. The expression was higher in adenomas than in normal human pituitary. In contrast, ACTH- and LH-FSH-secreting and non-secreting adenomas were negative. Seven transplants of the spontaneous rat prolactinoma SMtTW were also investigated and all were found to be positive. This further stresses the analogy between these tumours and human prolactinomas. Taken together, the data confirm that Pit-1/GHF-1 expression is restricted to GH-, prolactin- and TSH-expressing cells, and the increased expression in adenomas is compatible with a role of Pit-1/GHF-1 in cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8297469     DOI: 10.1677/jme.0.0110129

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  10 in total

1.  The dependence receptor Ret induces apoptosis in somatotrophs through a Pit-1/p53 pathway, preventing tumor growth.

Authors:  Carmen Cañibano; Noela L Rodriguez; Carmen Saez; Sulay Tovar; Montse Garcia-Lavandeira; Maria Grazia Borrello; Anxo Vidal; Frank Costantini; Miguel Japon; Carlos Dieguez; Clara V Alvarez
Journal:  EMBO J       Date:  2007-03-22       Impact factor: 11.598

2.  Neuroendocrine inhibition of glucose production and resistance to cancer in dwarf mice.

Authors:  J McKee Alderman; Kevin Flurkey; Natasha L Brooks; Sneha B Naik; Jonathan M Gutierrez; Urmila Srinivas; Kristen B Ziara; Linhong Jing; Gunnar Boysen; Rod Bronson; Simon Klebanov; Xian Chen; James A Swenberg; Mats Stridsberg; Carol E Parker; David E Harrison; Terry P Combs
Journal:  Exp Gerontol       Date:  2008-06-07       Impact factor: 4.032

3.  Role of prolactin in the in vitro development of interleukin-2-driven anti-tumoural lymphokine-activated killer cells.

Authors:  L Matera; G Bellone; J J Lebren; P A Kelly; E L Hooghe Peters; P F Di Celle; R Foa; M Contarini; G Avanzi; V Asnaghi
Journal:  Immunology       Date:  1996-12       Impact factor: 7.397

Review 4.  Molecular basis of pituitary oncogenesis.

Authors:  M Tada; H Kobayashi; T Moriuchi
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

Review 5.  Role of transcription factors in the pathogenesis of pituitary adenomas: a review.

Authors:  A Suhardja; K Kovacs; J Rutka
Journal:  J Neurooncol       Date:  2001-12       Impact factor: 4.130

6.  Reverse transcription polymerase chain reaction analysis of pituitary hormone, Pit-1 and steroidogenic factor-1 messenger RNA expression in pituitary tumors.

Authors:  M T McDermott; B R Haugen; D F Gordon; W M Wood; N S Brown; C A Bauer; M J Garrity; B K Kleinschmidt-DeMasters; K O Lillehei; M H Samuels; T M Bright; E C Ridgway
Journal:  Pituitary       Date:  1999-11       Impact factor: 4.107

7.  Loss of heterozygosity of the MEN1 gene in a large series of TSH-secreting pituitary adenomas.

Authors:  C Asteria; M Anagni; L Persani; P Beck-Peccoz
Journal:  J Endocrinol Invest       Date:  2001-11       Impact factor: 4.256

Review 8.  Gene expression in prolactinomas: a systematic review.

Authors:  Justin Seltzer; Thomas C Scotton; Keiko Kang; Gabriel Zada; John D Carmichael
Journal:  Pituitary       Date:  2016-02       Impact factor: 4.107

Review 9.  In search of a prognostic classification of endocrine pituitary tumors.

Authors:  Jacqueline Trouillas
Journal:  Endocr Pathol       Date:  2014-06       Impact factor: 3.943

10.  Advancements in the development of HIF-1α-activated protein switches for use in enzyme prodrug therapy.

Authors:  R Clay Wright; Arjun Khakhar; James R Eshleman; Marc Ostermeier
Journal:  PLoS One       Date:  2014-11-26       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.